

2015 Towards an HIV Cure Symposium
18 & 19 July 2015
Hyatt Regency Hotel, Vancouver, Canada

Saturday 18th July

08h30 – 09h00		Registration
09h00 – 09h20	Opening	Welcome and Introduction
09h20 – 9h50	Keynote	Progress and Challenges in HIV Cure Research Daniel Kuritzkes, Brigham & Women’s Hospital, Harvard Medical School, United States
9h50 – 10h05	Community	Community Involvement in HIV Cure-related Research: Not Just Guinea Pigs Matthew Sharp, Long-term Survivor, HIV Education and Advocacy Consultant, United States Chairs: Françoise Barré-Sinoussi, Inserm and Institut Pasteur, France and Jack Whitescarver, United States
10h05 – 11h25	Session 1	Pathways to establishing and maintaining HIV latency Chairs: Éric Cohen, Institut de Recherches Cliniques de Montréal, Canada and Michaela Muller-Trutwin, Institut Pasteur, France
10h05 – 10h25	Invited speaker	HIV-1 broadly neutralizing antibodies: Potential role in HIV treatment approaches John Mascola, Vaccine Research Center, NIAID/NIH, United States
10h25 – 10h40	OA1-1	CTLA-4-expressing memory CD4+ T-cells are critical contributors to SIV viral persistence Colleen McGary, Emory University, United States
10h40 -10h55	OA1-2	Molecular Determinants of HIV-1 Permissiveness and Persistence in Gut-Homing CD4+ T-Cells Expressing the Th17 Marker CCR6

Delphine Planas, CHUM-Research Center ; University of Montreal, Canada

10h55 – 11h10 OA1-3 **Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7**

Jose Alcamí, Instituto de Salud Carlos III, Spain

11h10 – 11h25 OA1-4 LB **Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs**

Jonathan Karn, Case Western Reserve University School of Medicine, United States

11h25 – 11h55 **Break**

11h55 – 13h00 Roundtable **Advancing Paediatric HIV Cure Research**

Chair: Jintanat Ananworanich, US Military HIV Research Program

Panelists:

Marie Elizabeth Theunissen, FAMCRU, South Africa

Hugo Soudeyns, CHU Sainte-Justine Research Center and Université de Montréal, Canada

Deborah Persaud, Johns Hopkins University, United States

Ann Chahroudi, Emory University School of Medicine, United States

Daria Hazuda, Merck, United States

13h00 – 14h00 **Lunch Break**

14h00 – 15h50 Session 2 **Activating latent HIV infection in vitro and in vivo**

Chairs: David Margolis, University of North Carolina, United States and Monique Nijhuis, University Medical Center Utrecht, Netherlands

14h00 – 14h20 Invited speaker **Immune recognition following latency reversal**

Marcus Altfeld, Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology Hamburg, Germany

14h20 – 14h35 OA2-1 **Histone deacetylase inhibitors alter the accumulation of spliced HIV mRNA - implications for virus production**

Talia Mota, Doherty Institute, The University of Melbourne, Australia

- 14h35 – 14h50 OA2-2 **Latency reversal Agent (LRA) Romidepsin Reactivates Latent Virus in Two Rhesus Macaque (RM) Models of Controlled SIV Infection in the Absence of Antiretroviral Therapy (ART)**
- Benjamin Policicchio, University of Pittsburgh, United States
- 14h50 – 15h05 OA2-3 **Vorinostat, Panobinostat, and Romidepsin Nonselectively Activate Transcription from Quiescent HIV-1 Proviruses in HIV-infected Individuals on Long-term Suppressive Anti-retroviral Therapy**
- Kirston Barton, University of Sydney, Australia
- 15h05 – 15h20 OA2-4 **Modulation of HERV family expression after treatment with HDAC inhibitors**
- Miguel de Mulder Rougvie, George Washington University, United States
- 15h20 – 15h35 OA2-5 **Ingenol Efficiently Reactivates Latent HIV in cells from aviremic patients**
- Vicente Planelles, University of Utah, United States
- 15h35 – 15h50 OA2-6 LB **CD4 Mimetics Sensitize HIV-1-Infected Cells to ADCC**
- Andres Finzi, The CHUM Research Center, University of Montreal & McGill University, Canada

15h50 – 17h00 Roundtable **Combination Therapy Trials**

Chair: Daniel Kuritzkes, Brigham & Women's Hospital, Harvard Medical School

Panelists:

Brigitte Autran, Hôpital Pitié Salpêtrière, CIMI-Paris, UPMC/INSERM U1135, France

Joseph Eron, University of North Carolina, United States

Irina Tcherepanova, Argos Therapeutics, Inc., United States

Jeffrey Lifson, Frederick National Laboratory for Cancer Research, United States

David Evans, Project Inform, United States

17h00 – 18h30 Poster Exhibition & Networking Session

Sunday 19th July

09h00 – 10h35	Session 3	Novel strategies to identify and quantify virus persistence in vivo (biomarkers) Chairs: Jean-Pierre Routy, McGill University Health Centre, Royal Victoria Hospital, Canada and Gabriela Turk, Instituto Investigaciones Biomédicas en Retrovirus y SIDA, Argentina
09h00 – 09h20	Invited speaker	Engineering T cells to functionally cure HIV-1 infection James Riley, Perelman School of Medicine, University of Pennsylvania, United States
09h20 – 09h35	OA3-1	Immunological Markers associated with HIV Persistence During ART Identified by Iterated Conditional Random Forests Analysis Remi Fromentin, CRCHUM, Canada
09h35 -9h50	OA3-2	Patient-derived defective HIV-1 proviruses containing large internal deletions can be transcribed and translated Ross Pollack, The Johns Hopkins University, United States
9h50 – 10h05	OA3-3	Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4+ T-cell count at 96 weeks ART Alexander Pasternak, Academic Medical Center of the University of Amsterdam, Netherlands
10h05 – 10h20	OA3-4	Distinct HIV Genetic Populations in Effector Memory T-cells after Prolonged Therapy Eunok Lee, Westmead Millennium Institute for Medical Research ; University of Sydney, Australia
10h20 – 10h35	OA3-5 LB	Investigating the Role of the Immune Checkpoint Receptor TIGIT in T cells during HIV Disease Progression and as a Target for Immune Restoration Glen Chew, University of Hawaii, United States
10h35 – 11h00		Break
11h00 – 12h35	Session 4	Immunology and persistence

Chairs: Di Yu, Monash University, Australia and Sarah Read, NIAID/DAIDS, NIH, United States

- 11h00 – 11h20 Invited speaker **CHERUB: Collaboration in HIV Eradication in the UK; Predictors of PTC and Viral Reactivation Strategies**
Sarah Fidler, Imperial College London, United Kingdom
- 11h20 – 11h35 OA4-1 **Trascriptomics and Metabolomics identify inflammatory profiles that segregate subjects with High and Low inducible HIV reservoir**
Rafick-Pierre Sekaly, Case Western Reserve University, United States
- 11h35 – 11h50 OA4-2 **Virologic and immunologic correlates of viral control post-ART interruption in SIV-infected rhesus macaques**
Mirko Paiardini, Emory University, United States
- 11h50 – 12h05 OA4-3 **Zinc Finger Nuclease Gene Editing for Functional Cure in a Nonhuman Primate Model of HIV/AIDS**
Christopher Peterson, Fred Hutchinson Cancer Research Center, United States
- 12h05 – 12h20 OA4-4 LB **HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child**
Asier Saez-Cirion, Institut Pasteur, France
- 12h20 – 12h35 OA4-5 LB **A Novel Therapeutic HIV-1 Vaccine Trial in Patients under HAART**
Frank Tung, GeneCure Biotechnologies, United States

12h35-14h00 Lunch Break

- 14h00 – 15h00 Roundtable **Key Partnerships: Community & Private Sector**
Chair: Sharon Lewin, Doherty Institute, The University of Melbourne
Panelists:
David Margolis, University of North Carolina at Chapel Hill, United States
Andrew Spaltenstein, GlaxoSmithKline, United States
Lynda Dee, CARE CAB; AIDS Action Baltimore, United States
Erik Iverson, Infectious Diseases Research Institute, United States

Veronica Miller, UC Berkeley; Forum for HIV Collaborative Research, United States

15h00 – 15h30 Closing Lecture

HBV Cure: Possible Lessons for HIV-AIDS

Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, Australia

Chair: Steven Deeks, University of California, San Francisco, United States

15h30 – 15h45

IAS-ANRS HIV Cure Young Investigator Prize Ceremony

Chairs: Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, United States and Jean-François Delfraissy, ANRS, France

15h45 – 16h00 Closing

Closing Remarks

Françoise Barré-Sinoussi, Institut Pasteur & Inserm, France
Carl Dieffenbach, NIAID/NIH, United States